Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Business & Regulation

Business & Regulation Quality & Compliance

Batch Relief

| James Strachan

EU will allow companies to carry out QC testing in the UK after a "no deal" Brexit, at least under certain conditions and for a limited time.

Business & Regulation Advanced Medicine

C&G Therapy? That’ll Do NICEly

| James Strachan

Nick Crabb explains the UK’s health technology assessment agency's (NICE's) approach to cell and gene therapies.

Business & Regulation Quality & Compliance

Animal-Free; Risk-Free

| Aaron Schieving

If you or your supplier are working with animal-derived components, you run the risk of exposing patients to dangerous contaminations.

Business & Regulation Trends & Forecasts

Ask, and Ye Shall Receive

| James Strachan

Regardless of how Britain leaves the European Union, the global pharma industry must always lobby for positive change.

Business & Regulation Trends & Forecasts

Mergers and Big Decisions

| George Chressanthis, Randy Risser

Why the CVS-Aetna merger could be a transformative event for the pharmaceutical industry.

Business & Regulation Trends & Forecasts

Medicine Making in Europe

| Stephanie Sutton

EFPIA figures give a snapshot of drug development and innovation in Europe. Check out our infographic for some of the key stats.

Business & Regulation Business Practice

Facing the Brexit Trial

| James Strachan

No-deal Brexit poses unique challenges for the development and advanced therapy sectors, not least tight timelines and a limited ability to stockpile.

Business & Regulation Business Practice

China’s Changing Future

| Minzhang Chen

The Chinese pharmaceutical market is already more advanced than many in the West imagine – and it only looks set to go in one direction.

Business & Regulation Trends & Forecasts

Business-in-Brief

| Stephanie Sutton

Gene therapy deals, clinical trials transparency and sartan medicine reviews… what’s new for pharma in business?

Business & Regulation Standards & Regulation

The 411 on the US Government Shutdown

| Maryam Mahdi

What did the partial government shutdown mean for the US pharma industry?

Newsletter

Send me the latest from The Medicine Maker.

Sign up now

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register